Amgen submits denosumab BLA
Executive Summary
Amgen has submitted a BLA for its novel RANK ligand inhibitor denosumab for two indications: treatment and prevention of postmenopausal osteoporosis in women and bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The filing, announced Dec. 18, is supported by two Phase III pivotal studies with fracture endpoints. Analysts have projected the twice-yearly injectable fully human monoclonal antibody could be worth as much as $2.4 billion worldwide by 2016, just in the PMO indication (1"The Pink Sheet" DAILY, July 29, 2008)
You may also be interested in...
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.